Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Dabrafenib in Renal Impairment
NCT02852239Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dabrafenib + trametinib in melanoma (3 arms), sponsored by Novartis. Primary endpoints: Maximum plasma concentration, Area under the curve to the last measurable concentration and 8 more. Started Dec 2016; status: completed.
02
Drugs
dabrafenib + trametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02852239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02852239.